- Clinical Trials
- April 2024
- 60 Pages
Global
From €1208EUR$1,250USD£1,039GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1208EUR$1,250USD£1,039GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Clinical Trials
- January 2024
- 280 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1208EUR$1,250USD£1,039GBP
- Drug Pipelines
- January 2024
- 80 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- November 2023
- 630 Pages
Global
From €9184EUR$9,500USD£7,894GBP
- Report
- June 2023
- 245 Pages
Global
From €7250EUR$7,500USD£6,232GBP
- Report
- May 2023
- 220 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- February 2024
- 174 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- February 2024
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- February 2024
- 170 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- January 2024
- 182 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- January 2024
- 181 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- January 2024
- 182 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- November 2023
- 189 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- November 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more